BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with.

Business Wire • Aug 18, 2026

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution.

Business Wire • Aug 10, 2026

BeOne Medicines Q2 Earnings Call Highlights

BeOne Medicines NASDAQ: ONC reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued to expand across approved indications and global markets.

MarketBeat • Aug 5, 2026

BeOne Medicines AG (ONC) Q2 2026 Earnings Call Transcript

BeOne Medicines AG (ONC) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. announced financial results and corporate updates from the second quarter of 2026.

Business Wire • Aug 5, 2026

BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Aug 5, 2026

Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Zacks Investment Research • Aug 4, 2026

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. announced a $300 million expansion of its manufacturing and R&D center at the Princeton West Innovation Campus in Hopewell, NJ.

Business Wire • Jul 23, 2026

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com. To ensure a.

Business Wire • Jul 17, 2026

Baird International And Global Growth Funds Q2 2026 Contributors And Detractors

In the second quarter of 2026, the Baird Chautauqua International Growth Fund Net Investor Class returned +10.39%, underperforming the MSCI ACWI ex-U.S. Index® ND, which returned +14.49%. The largest relative detractors were Alibaba, Lululemon, and Brookfield Renewable, while the largest relative contributors were Recruit, ASML, and Keyence. The Baird Chautauqua Global Growth Fund Net Investor Class returned +12.18% during the quarter, underperforming the MSCI ACWI Index® ND, which returned +14.93%.

Seeking Alpha • Jul 13, 2026